Ny kunnskap om blodproppfaren ved hormonelle prevensjonsmidler
Engelsk titel: The risk of thromboembolism of hormonal contraceptives - updated knowledge
Läs online
Författare:
Harg, Pernille
;
Hortemo, Sigurd
Email: pernille.harg@legemiddelverket.no
Språk: Nor
Antal referenser: 17
Dokumenttyp:
Översikt
UI-nummer: 15063913
Sammanfattning
In 2014 European regulatory authorities decided that the product information for all combined
hormonal contraceptives (estrogen + progestogen) should be updated regarding the risk of
thrombosis. The updated information will help women make informed decisions about their choice of
contraception. The overall blood clot risk is slightly higher than previously assumed. The lowest risk
among the combined hormonal contraceptives is found in the combination of estrogen and
levonorgestrel / norethisterone. The risk of blood clots is highest during the first year of treatment
and after re-starting combined hormonal contraceptive after a period of non-use of at least a month. It
is recommended that women starting therapy with a combined hormonal contraceptive, starts with the
fixed combination of estrogen + levonorgestrel.